PD0325901

Licensed by Pfizer 製品コードS1036

PD0325901化学構造

分子量(MW):482.19

PD0325901は一種の選択性的で、非ATP競争性的なMEK阻害剤で、無細胞試験でIC50値が0.33 nMですが、ERK1とERK2のリン酸化を抑制する作用はCI-1040より500倍左右が高くなります。臨床2期。

サイズ 価格(税別)  
JPY 23240.00
JPY 11620.00
JPY 44820.00
JPY 127820.00

文献中の使用例(73)

カスタマーフィードバック(17)

  • Phosphorylation of PPARg in epididymal white adipose tissue in ob/ob mice after treatment with MEK inhibitors. Gene expression in ob/ob epididymal white adipose tissue after treatment with vehicle or either of two MEK inhibitors, PD0325901 or GSK1120212 (n = 7, 7 and 8, respectively). Areas under the curve and gene expression were analysed by analysis of variance.

    Nature 2015 517(7534), 391-5. PD0325901 purchased from Selleck.

    c, Examples of CDK2 activity traces aligned to the end of mitosis. Each panel shows different time windows relative to mitosis when mitogens were withdrawn (marked in grey) in d. d, Probability of proliferation (defined as CDK2 activity > 1, 10 h after mitosis) represented as a function of time when inhibitors of MEK (MEKi; 100 nM PD0325901) or of CDK4 (CDK4i; 1 μ M palbociclib) were added or when mitogens were removed, relative to mitosis. Data are mean ± s.e.m. (n = 5 biological replicates).

    Nature, 2017. PD0325901 purchased from Selleck.

  • Rapamycin reduces VCAM expression in vivo. Expression of VCAM-1 mRNA (normalized to CD31) in aortas harvested from mice pretreated with vehicle, rapamycin, or rapamycin + MEK inhibitor (MEK-I; PD0325901) and then injected with TNF (n = 5 per group). Mice were treated as in D. Harvested aortas were analyzed for VCAM-1 expression via immunofluorescence.

    J Exp Med 2014 211(3), 395-404. PD0325901 purchased from Selleck.

    Plasma MEK inhibitor levels of PD325901 are plotted against % MEK inhibition in brain. One hundred percent pERK levels (0% MEK inhibition) were determined in vehicle-treated rats.Inhibition of pERK activity in brain, lung, and Colo205 tumor in nude xenograft mice treated with 10 mg/kg PD325901.

     

     

    Cancer Res 2009 PD0325901 purchased from Selleck.

  • Pharmacological inhibition of MEK (PD0325901) suppresses DR5 expression in cancer cells; this effect is reversible upon stopping of the treatment. The indicated cancer cell lines were exposed to the given concentrations of the inhibitors as indicated for 16 h. TPC-1 cells were treated with 10 uM of the indicated inhibitors for different times as labeled.

    Oncogene 2015 10.1038/onc.2015.97. PD0325901 purchased from Selleck.

    (B)Effect of MAPK pathway inhibition on FGF9 mediated induction of Fgf23 expression. (D) Western blot analysis of FRS2 and ERK1/2 phosphorylation in UMR 106 cells. Cells were treated for 3h (Western blot) or 24h (qPCR analysis) with FGF9 (50ng/ml), EGF (50ng/ml), PD173074 (250nM), PD0325901 (100nM) and RAF265 (500nM) as indicated. Heparin (10g/ml) was added to all treatments with FGF9. Activation of Fgf23 is shown relative to transcript levels in vehicle treated cells (relative expression of 1). Expression values were normalized to Gapdh mRNA copies and are given as average with SEM (n3). Data were compared by 1 way ANOVA; asterisk indicates p<0.05 with respect to vehicle treated cells.

    J Bone Miner Res 2011 26, 2486-2497. PD0325901 purchased from Selleck.

  • Assessment of in vivo toxicity to MEK inhibitor PD0325901. (A) Weight change in grams is shown for each PD0325901 (PD) treatment group in the MDA-MB-453 xenograft model. Weight change is the difference between pre- and post-treatment weight in each group. PD0325901 treatments were carried out at 5, 10, 15 and 20 mg/kg/day for 30 days, and daily gavage of carrier solution was used as control. *P < 0.01 for PD-5/PD-10 vs. control groups and PD-5/PD-10 vs. PD-15/PD-20 groups using Mann-Whitney U test. Error bars: ±2 SEM. (B) Number of days lost due to toxicity is shown for each PD0325901 treatment group in mouse xenograft model explained in Figure 5A. *P < 0.01 for PD-5/PD-10 vs. PD-15/PD-20 groups.

     

     

    Breast Cancer Res 2011 13, R36. PD0325901 purchased from Selleck.

    The therapeutic effect of AR and MEK inhibitors on in vivo angiogenesis. (A) Angiogenesis index for each in vivo treatment group. Angiogenesis was measured as the number of CD-31-positive blood vessels in a cross-section of each xenograft tumor. CTL: control group; FLU: flutamide; and PD: PD0325901. *P < 0.03 for PD0325901 monotherapy vs. control and **P < 0.03 for combination therapy vs. monotherapy groups using Mann-Whitney U test. Error bars: ±2 SEM. (B) Immunohistochemistry (IHC) was used to measure angiogenesis in a control xenograft tumor. Staining was performed using a CD31 rabbit polyclonal antibody. Original magnification, × 40. (C) IHC was used to measure angiogenesis in a PD0325901 monotherapy tumor. Original magnification, × 40. (D) IHC was used to measure angiogenesis in a xenograft tumor treated with combination therapy. Original magnification, × 40.

    Breast Cancer Res 2011 13, R36. PD0325901 purchased from Selleck.

  • Effects of the MEK inhibitor (MEKi) PD0325901 (PD) and rhBMP-2 (BMP) treatment on histology in an NF1 open fracture model. Treatment with 10 mg/kg of PD0325901 on days 22 through 10 (PD alone) slightly improved bone volume and callus size. Delivery of 10 mg of rhBMP-2 in the collagen sponge (BMP alone) resulted in a large increase in bone volume and callus size. Combination treatment with local rhBMP-2 and systemic PD0325901 (PD 1 BMP) resulted in further increases in new bone volume and total callus volume.Picro Sirius Red and Alcian Blue staining to assess fibrous tissue.

    J Bone Joint Surg Am 2015 96(14), e117. PD0325901 purchased from Selleck.

    Bone 2014 59, 151-61. PD0325901 purchased from Selleck.

  •  

    Effect of small molecule inhibitors on reprogramming efficiency of myoblast cell derived from 5 different donors. (A) Reprogramming efficiency is shown as number of colonies from 10^5 starting cells on Y-axes. Ctrl, control condition and addition of small molecule inhibitors are marked. (B) AP staining of reprogrammed myoblast cell lines,from 5 different donors, in wells of 12-well plates at day 18. Ctrl, control condition and additions of small molecule inhibitors are marked.

    Stem Cells Dev 2013 PD0325901 purchased from Selleck.

     

    Characterization of rES cells. A: image of normal rES cell colonies on feeder layers. B: rES colonies were positive for AP staining. CeE: rES colonies readily expressed pluripotent markers, Sox2 (C), Oct4 (D), and SSEA-1 (E). Blue, DAPI. Scale bars: 100 um.

    J Genet Genomics 2012 39, 643e651. PD0325901 purchased from Selleck.

  • The effects of PD0325901 on the Akt/mTOR and MAPK pathways in the two DDLS cell lines as evaluated by western blotting

    Tumour Biol, 2016, 37(4):4767-76.. PD0325901 purchased from Selleck.

    PD0325901 inhibited the sorafenib-induced RAS/ERK pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (PD0325901, 10 μM). Expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (PD0325901, 10 μM). Expressions of p-AKT and cleaved PARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. Proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. Proportions of apoptotic cells were evaluated by annexin V labeling. (*P<0.05, HUH- 7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. PD0325901 purchased from Selleck.

  • Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. PD0325901 purchased from Selleck.

    Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of  PD0325901 for 24 hours.

     

     

    2010 Dr Zhang of Tianjin Medical University. PD0325901 purchased from Selleck.

  • Effects of PD0325901 on HT29 Xenograft tumors. PD0325901(1mg/kg carrier DMSO).Collection at 24h.

     

     

    2010 Dr. Citrin, Deborah of NIH. PD0325901 purchased from Selleck.

製品安全説明書

MEK阻害剤の選択性比較

生物活性

製品説明 PD0325901は一種の選択性的で、非ATP競争性的なMEK阻害剤で、無細胞試験でIC50値が0.33 nMですが、ERK1とERK2のリン酸化を抑制する作用はCI-1040より500倍左右が高くなります。臨床2期。
ターゲット
MEK [1]
(Cell-free assay)
0.33 nM
体外試験

PD0325901 shows higher permeability than CI-1040, another MEK inhibitor. PD0325901 should be able to achieve higher systemic exposures than CI-1040. [1] PD0325901 is exquisitely specific and highly potent against purified MEK, revealing a Kiapp of 1 nM against activated MEK1 and MEK2. [2] PD0325901 is roughly 500-fold more potent than CI-1040 with respect to its cellular effects on phosphorylation of ERK1 and ERK2, displaying subnanomolar activity. [2] PD0325901 prevents the growth of melanoma cell lines. PD0325901 inhibits the growth of TPC-1 cells and K2 cells with GI50 of 11 nM and 6.3 nM, respectively. [3] PD0325901 significantly prevents the the growth of PTC cells harboring a BRAF mutation at very low concentration (10 nM) and only moderately increases the growth of the PTC cells carrying the RET/PTC1 rearrangement at the same concentration. PD0325901 effectively inhibits the phosphorylation of ERK1/2 in multiple PTC cell lines. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human CHP-212 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX63Nm82UW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC53Mkegcm0v NVG4N2NJW0GQR1XS
human M14 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWXlfWlJUW6qaXLpeIlwdiCxZjDoeY1idiCPMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQ2KG6PLh?= M2C5fnNCVkeHUh?=
human SK-MEL-28 cell MnLVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1vrVmlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVI5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS53MjDuUU4> MmXoV2FPT0WU
human NOMO-1 cell M1K1cGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkfZTY5pcWKrdHnvckBw\iCqdX3hckBPV02RLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlA4KG6PLh?= NWDCO2VFW0GQR1XS
human A375 cell NY\6eFJbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWXJcohq[mm2aX;uJI9nKGi3bXHuJGE{PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lk[5JI5ONg>? NVHFc|c4W0GQR1XS
human DU-4475 cell NI\BO29Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGOxPZVKdmirYnn0bY9vKG:oIHj1cYFvKESXLUS0O|Uh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjV5IH7NMi=> M13ucnNCVkeHUh?=
human C32 cell M2LXXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnjyTY5pcWKrdHnvckBw\iCqdX3hckBEOzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|Lk[3JI5ONg>? NX7hbo94W0GQR1XS
human BPH-1 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEHNbo5KdmirYnn0bY9vKG:oIHj1cYFvKEKSSD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{46PSCwTT6= M3y2d3NCVkeHUh?=
human CP50-MEL-B cell NH\Sd2NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYPJcohq[mm2aX;uJI9nKGi3bXHuJGNRPTBvTVXMMWIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjV6IH7NMi=> NIT1NGhUSU6JRWK=
human H9 cell MnO0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYPJcohq[mm2aX;uJI9nKGi3bXHuJGg6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS55NzDuUU4> Moe3V2FPT0WU
human HTC-C3 cell NWX0OIM{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGPtbYpKdmirYnn0bY9vKG:oIHj1cYFvKEiWQz3DN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQDlibl2u M{\RbHNCVkeHUh?=
human BHT-101 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGJJXC1zMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22Mlchdk1w NITKUGVUSU6JRWK=
human COLO-741 cell NWSwV4tYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnnBTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUe0NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOSCwTT6= NXe0[ZdvW0GQR1XS
human OVCAR-5 cell MlS5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mm\FTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45OiCwTT6= MXzTRW5ITVJ?
human A549 cell NIqzRVBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnvpTY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64PUBvVS5? M175c3NCVkeHUh?=
human SH-4 cell growth NH3wNphIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2TT[mlvcGmkaYTpc44hd2ZiaIXtZY4hW0hvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNlYhdk1w NUPFeG9NW0GQR1XS
human SK-N-AS cell NUm1S5NmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXTJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU5vQWOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlQ1KG6PLh?= Mm\UV2FPT0WU
human HT-144 cell MmLkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYLjfnl{UW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xOFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05Njl5IH7NMi=> MYrTRW5ITVJ?
human MEL-HO cell NXPwVHFwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3LLd2lvcGmkaYTpc44hd2ZiaIXtZY4hVUWOLVjPJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU41QSCwTT6= NEK3PXlUSU6JRWK=
human COLO-679 cell M1TXPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYnJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vNke5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVAvODFibl2= MUTTRW5ITVJ?
human HuP-T4 cell Mn3ES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUX5V2Y5UW6qaXLpeIlwdiCxZjDoeY1idiCKdWCtWFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC57ODDuUU4> MY\TRW5ITVJ?
human H-EMC-SS cell MmnxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXTJcohq[mm2aX;uJI9nKGi3bXHuJGguTU2FLWPTJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvODJibl2u M{fXTnNCVkeHUh?=
human LB2518-MEL cell NYLRSXRIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{LofWlvcGmkaYTpc44hd2ZiaIXtZY4hVEJ{NUG4MW1GVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFzLkGzJI5ONg>? MU\TRW5ITVJ?
human HL-60 cell NFT2cHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MofZTY5pcWKrdHnvckBw\iCqdX3hckBJVC14MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxMlE2KG6PLh?= NV:zOmI3W0GQR1XS
human NCI-H1666 cell NFPGfXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnzLTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG2OlYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOS5zNzDuUU4> NWT2UINVW0GQR1XS
human A101D cell NF6xSVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYm5UW1qUW6qaXLpeIlwdiCxZjDoeY1idiCDMUCxSEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNjR3IH7NMi=> Ml\CV2FPT0WU
human RVH-421 cell MoP5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYX6Rnh2UW6qaXLpeIlwdiCxZjDoeY1idiCUVlitOFIyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTJwNkSgcm0v NXzMRoFJW0GQR1XS
human Hs-578-T cell MlPJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIHaU4RKdmirYnn0bY9vKG:oIHj1cYFvKEi|LUW3PE1VKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTJwN{mgcm0v NXfzNlV3W0GQR1XS
human A375 cells NYjhXmF{WHKxbHnm[ZJifGmxbjDhd5NigQ>? MYq3NkBp NFvCeYRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGzO|Uh[2WubIOg[ZhxemW|c3nu[{BDWkGIIG[2NFBGKG23dHHueEBi\nSncjC3NkBpenNiYomgR4VtdCC2aYTldk1odG9iYYPzZZktKEmFNUC9NVMhdk1w M37vV|I{PDd2M{i4
human DOK cell M{Tub2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH[zdWZKdmirYnn0bY9vKG:oIHj1cYFvKESRSzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGzMlQhdk1w NGD4cZBUSU6JRWK=
human Mewo cell NWPBe|hYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFO5elBKdmirYnn0bY9vKG:oIHj1cYFvKE2nd3:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOE41PSCwTT6= MmXUV2FPT0WU
human ONS-76 cell Ml3kS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH30R5hKdmirYnn0bY9vKG:oIHj1cYFvKE:QUz23OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjVzIH7NMi=> M4jU[XNCVkeHUh?=
human UACC-257 cell MkDWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkXnTY5pcWKrdHnvckBw\iCqdX3hckBWSUOFLUK1O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjZ{IH7NMi=> MoOyV2FPT0WU
human SW626 cell NV3ZbZFiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXLDWVlHUW6qaXLpeIlwdiCxZjDoeY1idiCVV{[yOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjlzIH7NMi=> NW\XWXU6W0GQR1XS
human SW620 cell NUiyR2N5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3flWmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d4MkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOE46PSCwTT6= M2nzfHNCVkeHUh?=
human TYK-nu cell MmrDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEftVmRKdmirYnn0bY9vKG:oIHj1cYFvKFS\Sz3ueUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE2NjF|IH7NMi=> MVvTRW5ITVJ?
human ACN cell NV3odG9mT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkXtTY5pcWKrdHnvckBw\iCqdX3hckBCS05iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNT63OkBvVS5? M37sOnNCVkeHUh?=
human MIAPaCa2 cells M{CwZXBzd2yrZnXyZZRqd25iYYPzZZk> M4HmO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVnBVIFE[TJiY3XscJMtKEmFNUC9NVchdk1w Ml\MNlM1PzR|OEi=
human T-24 cell NYLzPZpLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkfuTY5pcWKrdHnvckBw\iCqdX3hckBVNTJ2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUmuO|Ehdk1w Mnj6V2FPT0WU
human AGS cell M3znXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml\VTY5pcWKrdHnvckBw\iCqdX3hckBCT1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{MD60NUBvVS5? NWHkRZRyW0GQR1XS
human SW872 cell M1PRWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXzJcohq[mm2aX;uJI9nKGi3bXHuJHNYQDd{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkeuPVkhdk1w M{PYNnNCVkeHUh?=
human C2BBe1 cell Ml\CS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXHJcohq[mm2aX;uJI9nKGi3bXHuJGMzSkKnMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK4MlU1KG6PLh?= NGrIT41USU6JRWK=
human MZ7-mel cell M4e1S2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH7jNFlKdmirYnn0bY9vKG:oIHj1cYFvKE2cNz3t[Ywh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zQS52MzDuUU4> MWTTRW5ITVJ?
human HCC2998 cell Mm[1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUPJcohq[mm2aX;uJI9nKGi3bXHuJGhESzJ7OUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zN{43PiCwTT6= NF7tO4VUSU6JRWK=
human HO-1-N-1 cell M1;ldmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH3DNGRKdmirYnn0bY9vKG:oIHj1cYFvKEiRLUGtUk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzRwNEOgcm0v NU\LOFRUW0GQR1XS
human SW756 cell MluwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYnJcohq[mm2aX;uJI9nKGi3bXHuJHNYPzV4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{SuOFUhdk1w Mlr4V2FPT0WU
human NCI-H1437 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUSzO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1NjR7IH7NMi=> NX3ZUHZtW0GQR1XS
human NCI-H747 cell MnLGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnfjTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEe0O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1Njl6IH7NMi=> MWPTRW5ITVJ?
human SK-MEL-2 cell M4j2Z2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkjkTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM2NjJibl2u NH7hcVJUSU6JRWK=
human MZ2-MEL cell M2Gz[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH\yOodKdmirYnn0bY9vKG:oIHj1cYFvKE2cMj3NSWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{PS54NTDuUU4> NHq3[INUSU6JRWK=
human PSN1 cell NYP2UYhFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFXvZWdKdmirYnn0bY9vKG:oIHj1cYFvKFCVTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zPE41PSCwTR?= M4jNOnNCVkeHUh?=
human CAL-39 cell NIO4N|BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmTWTY5pcWKrdHnvckBw\iCqdX3hckBESUxvM{mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zPU4xPCCwTT6= NIniNVFUSU6JRWK=
human LOXIMVI cell MlzXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2HLZ2lvcGmkaYTpc44hd2ZiaIXtZY4hVE:[SV3WTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM6NjN7IH7NMi=> M{nRbnNCVkeHUh?=
human COLO-792 cell Ml[1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmfRTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUe5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ{NjF3IH7NMi=> NEXu[otUSU6JRWK=
human CAL-27 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{C4V2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFQvQTFibl2= MXzTRW5ITVJ?
human AsPC-1 cell NWrjSVd1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1:3SmlvcGmkaYTpc44hd2ZiaIXtZY4hSXOSQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFUvOjhibl2u NXfERmRJW0GQR1XS
human NCI-H2291 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGT4ZYpKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlI6OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTR4LkS2JI5ONg>? NVna[VdWW0GQR1XS
human RCM-1 cell M{DZdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3jPVmlvcGmkaYTpc44hd2ZiaIXtZY4hWkOPLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Ok45PSCwTT6= M33GXnNCVkeHUh?=
human NCI-H292 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV3Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFcvOzlibl2u NVLEXJFKW0GQR1XS
human WM-115 cell NUfWcFhyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXXJcohq[mm2aX;uJI9nKGi3bXHuJHdONTFzNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS4MlUhdk1w MonIV2FPT0WU
human RT-112 cell Ml;wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH\yfmlKdmirYnn0bY9vKG:oIHj1cYFvKFKWLUGxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ5Njh2IH7NMi=> M4LxTHNCVkeHUh?=
human HT-29 cell NX23[40zT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX\BcGFTUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2yPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUxNjR7IH7NMi=> Ml\1V2FPT0WU
human RKO cell growth NYjB[4pQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX\Jcohq[mm2aX;uJI9nKGi3bXHuJHJMVyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTV{LkCyJI5ONg>? MWfTRW5ITVJ?
human KY821 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn72TY5pcWKrdHnvckBw\iCqdX3hckBMYTh{MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWzMlMhdk1w MmnSV2FPT0WU
human LB1047-RCC cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGxDOTB2Nz3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02QS54NTDuUU4> NInXSnFUSU6JRWK=
human SW1116 cell NVrDWVFjT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWPRXIpsUW6qaXLpeIlwdiCxZjDoeY1idiCVV{GxNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03OC52OTDuUU4> NWrhUGlGW0GQR1XS
human P12-ICHIKAWA cell NWfY[YFrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEOybodKdmirYnn0bY9vKG:oIHj1cYFvKFBzMj3JR2hKU0GZQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[yMlI4KG6PLh?= MmrPV2FPT0WU
human HCC70 cell NYX4N3FpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4XjSWlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFN{CgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22N{4xOSCwTT6= MXLTRW5ITVJ?
human MIA-PaCa-2 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUXJcohq[mm2aX;uJI9nKGi3bXHuJG1KSS2SYVPhMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03Oy53MzDuUU4> NXzY[WZTW0GQR1XS
human LoVo cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml\GTY5pcWKrdHnvckBw\iCqdX3hckBNd1[xIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NkWuNlkhdk1w MX\TRW5ITVJ?
human LB2241-RCC cell M3nHSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkLOTY5pcWKrdHnvckBw\iCqdX3hckBNSjJ{NEGtVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjVwNUKgcm0v NUTOe4lRW0GQR1XS
human GAK cell NYHVelNJT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHXrZmNKdmirYnn0bY9vKG:oIHj1cYFvKEeDSzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[2Mlg4KG6PLh?= NGPaVHJUSU6JRWK=
human RD cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYjHXWdsUW6qaXLpeIlwdiCxZjDoeY1idiCURDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[3MlEhdk1w NVL0dY1ZW0GQR1XS
human KNS-62 cell NYOybnByT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVnJcohq[mm2aX;uJI9nKGi3bXHuJGtPWy14MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[5Mlk6KG6PLh?= MULTRW5ITVJ?
human HD-MY-Z cell MnjUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml3JTY5pcWKrdHnvckBw\iCqdX3hckBJTC2PWT3aJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|EvOTJibl2u M3PLfXNCVkeHUh?=
human COR-L105 cell NGPFTolIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYnJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|EvPzFibl2u NHfaOI9USU6JRWK=
human IA-LM cell NYDQTVNrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmnLTY5pcWKrdHnvckBw\iCqdX3hckBKSS2OTTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUezMlI5KG6PLh?= MYXTRW5ITVJ?
human EM-2 cell NUWyTGdlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1vYOGlvcGmkaYTpc44hd2ZiaIXtZY4hTU1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUe0Mlchdk1w MnzoV2FPT0WU
human NB69 cell NVq0VGpST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVjJcohq[mm2aX;uJI9nKGi3bXHuJG5DPjliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeR?= MWXTRW5ITVJ?
human HuP-T3 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2\IeWlvcGmkaYTpc44hd2ZiaIXtZY4hUHWSLWSzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFMvQTNibl2u M3HMcXNCVkeHUh?=
human BB30-HNC cell NXfUbHY{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUHJcohq[mm2aX;uJI9nKGi3bXHuJGJDOzBvSF7DJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFUvPTFibl2u MofDV2FPT0WU
human HT-1080 cell M2q2TWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHv3OGRKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05PS56ODDuUU4> NHy1ZYJUSU6JRWK=
human RMG-I cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWnifIRuUW6qaXLpeIlwdiCxZjDoeY1idiCUTVetTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVg4NjN2IH7NMi=> NHraUFVUSU6JRWK=
human HCC1419 cell NWn6PVdZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NELYcZlKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{G0NVkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06OS5|ODDuUU4> MorLV2FPT0WU
human SW780 cell M{\afWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUXqRYZHUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkzNjN{IH7NMi=> M{jSfnNCVkeHUh?=
human SNU-387 cell MonZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUjFZVJmUW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtN|g4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QTNwM{[gcm0> M4noRnNCVkeHUh?=
human LAMA-84 cell NIPNbpBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml7OTY5pcWKrdHnvckBw\iCqdX3hckBNSU2DLUi0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PVQvPjhibl2u NFH0c4pUSU6JRWK=
human MV-4-11 cell NFPkbZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3zRemlvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVk1Njd|IH7NMi=> NIezXphUSU6JRWK=
human EGI-1 cell M33KU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mo\4TY5pcWKrdHnvckBw\iCqdX3hckBGT0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUm1MlgyKG6PLh?= MVTTRW5ITVJ?
human NCI-SNU-1 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2VTmWtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVk3Njd|IH7NMi=> NYPs[3lwW0GQR1XS
human MEG-01 cell M3LPSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFHmTHFKdmirYnn0bY9vKG:oIHj1cYFvKE2HRz2wNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVk4Njd5IH7NMi=> MX7TRW5ITVJ?
human OMC-1 cell MkXmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVrJcohq[mm2aX;uJI9nKGi3bXHuJG9OSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUCwMlI{KG6PLh?= NHLke3BUSU6JRWK=
human NB10 cell NXzFWXFLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4HPR2lvcGmkaYTpc44hd2ZiaIXtZY4hVkJzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwNE41OiCwTT6= MUPTRW5ITVJ?
human CAL-62 cell MnT1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlnmTY5pcWKrdHnvckBw\iCqdX3hckBESUxvNkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNFAvPzhibl2u NV3WWIJtW0GQR1XS
human NCI-H2087 cell NGjyUlhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWH5XHRHUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxQDdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMEGuNVQhdk1w MUfTRW5ITVJ?
human MDA-MB-175-VII cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWfJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xO|UuXkmLIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYm= MYnTRW5ITVJ?
human LS-513 cell M1LofWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXT3UmRDUW6qaXLpeIlwdiCxZjDoeY1idiCOUz21NVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOTRwOEOgcm0v MWfTRW5ITVJ?
human HN cell growth MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnjOTY5pcWKrdHnvckBw\iCqdX3hckBJViClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF{Mj61PUBvVS5? MUjTRW5ITVJ?
human ABC-1 cell MmfUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUHJcohq[mm2aX;uJI9nKGi3bXHuJGFDSy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUKzMlAzKG6PLh?= NFnme2NUSU6JRWK=
human SJSA-1 cell NHKzZ49Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NInP[VNKdmirYnn0bY9vKG:oIHj1cYFvKFOMU1GtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEzOy5zOTDuUU4> NFy3RYRUSU6JRWK=
human PANC1 cells Ml\SSpVv[3Srb36gZZN{[Xl? NXvM[3U2OTBizszN MXixJIg> NH7VOIJKdmirYnn0bY9vKG:oIF3FT|EhcW5iaIXtZY4hWEGQQ{GgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKHCHcnuxM|IhdGW4ZXygZZQhOTBidV2gZYZ1\XJiMTDodkBjgSCZZYP0[ZJvKGKub4T0bY5oKGGwYXz5d4l{ NIfuTY0zPTd4Nk[zNy=>
human MCF7 cells MWPGeY5kfGmxbjDhd5NigQ>? M3SwcFc2KG2rboO= NFnreZFKdmirYnn0bY9vKG:oIF3Fb|EwOiCrbjDoeY1idiCPQ1[3JINmdGy|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKEWUSzDwbI9{eGixconsZZRqd25iYX\0[ZIhPzVibXnud{BjgSCZZYP0[ZJvKGKub4T0bY5oKGGwYXz5d4l{ NEjxSYkzOzN7OES1Ny=>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 The improved potency of PD0325901 relative to CI-1040 is evident. A single oral dose of PD0325901 (25 mg/kg) inhibits phosphorylation of ERK by more than 50% at 24 hours post-dosing. In contrast, CI-1040 at a much higher dose (150 mg/kg) only inhibit pERK levels for roughly 8 hours, returning to control levels by 24 hours after treatment. [2] Therefore, the dose required to produce a 70% incidence of complete tumor responses (C26 model) is 25 mg/kg/day versus 900 mg/kg/day for PD0325901 and CI-1040, respectively. Anticancer activity of PD 0325901 has been demonstrated for a broad spectrum of human tumor xenografts. [2] After 1 week of oral administration of PD0325901 (20–25 mg/kg/day) in mice, no tumor growth is detected in mice inoculated with PTC cells bearing a BRAF mutation. [3] For PTC with the RET/PTC1 rearrangement, the average tumor volume of the orthotopic tumor is decreased by 58% as compared with controls. In conclusion, PTC cells carrying a BRAF mutation are more sensitive to PD0325901 than are PTC cells carrying the RET/PTC1 rearrangement. [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

In vitro cascade assay:

Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of a glutathione S-transferase fusion protein containing p44MAP kinase (GST-MAPK) and a glutathione S-transferase protein containing p45MEK (GST-MEK). The assay solution contained 20 mM HEPES, pH 7.4, 10 mM MgCl2, 1 mM MnCl2, 1 mM EGTA, 50 mM [gamma-32P]ATP, 10 mg GST-MEK, 0.5 mg GST-MAPK and 40 mg MBP in a final volume of 100 mL. Reactions are stopped after 20 minutes by addition of trichloroacetic acid and filtered through a GF/C filter mat. 32P retained on the filter mat is determined using a 1205 Betaplate. PD0325901 is assessed at various dose ranges in order to determine dose response curves.
細胞試験:

[3]

+ 展開
  • 細胞株: PTC cells
  • 濃度: 0.1 nM- 1 μM
  • 反応時間: 48 hours
  • 実験の流れ:

    PTC cells (1 × 104) are seeded in 24-well plates with 1 mL of medium for 4 days in a 37 °C incubator. MEK inhibitor PD0325901 at varying concentrations is added to the cells in triplicate on day 0. MTT dissolved in 0.8% NaCl solution at 5 mg/mL is added to each well (0.2 mL) on day 2 to test GI50 or every day for cell growth curves. The cells are incubated at 37 °C for 3 hours with MTT. The liquid is then aspirated from the wells and discarded. Stained cells are dissolved in 0.5 mL of DMSO and their absorption at 570 nm is measured using a Synergy HT multidetection microplate reader. For GI50, cell growth is calculated as 100 × (T − T0)/(C − T0), where T is the optical density of the wells treated with inhibitors after a 48-hour period, T0 is the optical density at time zero, and C is the control optical density with DMSO only.


    (参考用のみ)
動物試験:

[3]

+ 展開
  • 動物モデル: Ncr-nu/nu mice bearing PTC cells
  • 製剤: 80 mM citric buffer (pH 7)
  • 投薬量: 20-25 mg/kg
  • 投与方法: Oral gavage
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 96 mg/mL (199.09 mM)
Ethanol 40 mg/mL (82.95 mM)
Water Insoluble
体内 順序で溶剤を入れること:
30% PEG 400+5% Tween 80+ddH2O
10mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 482.19
化学式

C16H14F3IN2O4

CAS No. 391210-10-9
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02510001 Recruiting Solid Tumour|Colorectal Cancer University of Oxford|Queens University, Belfast|Oxford University Hospitals NHS Trust|Velindre NHS Trust|University Hospital, Antwerp|Hospital Vall dHebron|Hopital St Antoine, Paris|European Georges Pompidou Hospital|Pfizer|University of Turin, Italy|Belfast Health and Social Care Trust|Beaumont Hospital|European Commission|Array BioPharma|Q2 solutions|Covance|QPS Holdings November 2014 Phase 1
NCT02096471 Active, not recruiting Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN University of Alabama at Birmingham June 2014 Phase 2
NCT02022982 Recruiting KRAS Mutant Non-Small Cell Lung Cancer|Solid Tumors Dana-Farber Cancer Institute January 2014 Phase 1|Phase 2
NCT02039336 Recruiting Colorectal Cancer The Netherlands Cancer Institute|Pfizer January 2014 Phase 1|Phase 2
NCT02297802 No longer available Prior Treatment With PD-0325901 With Ongoing Clinical Response Sharp HealthCare June 2013 Phase 1
NCT01347866 Terminated Advanced Cancer Pfizer October 2011 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Whether the inhibitor PD0325901 interacts with other targets other than MEK?

  • 回答:

    PD0325901 has very high selectivity to MEK. In addition, it can also inhibits VEGF activity according to the reference: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713590/

Related Antibodies

MEK信号経路図

MEK Inhibitors with Unique Features

相関MEK製品

Tags: PD0325901を買う | PD0325901 ic50 | PD0325901供給者 | PD0325901を購入する | PD0325901費用 | PD0325901生産者 | オーダーPD0325901 | PD0325901化学構造 | PD0325901分子量 | PD0325901代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID